Profile: Morvus Technology Limited is a pharmaceutical company specialising in the discovery and commercialisation of novel drugs for the oncology market. We offer nucleoside-based anti-cancer drugs. Our mortar platform technology identifies new proteins and genes that share the ability to inhibit apoptosis(programmed cell death). Aberrant production of proteins that inhibit apoptosis causes diverse diseases such as cancer, neurodegeneration, rheumatoid arthritis, cardiovascular disease and viral & bacterial infections. We have two technology platforms based around enzyme-prodrug interactions. The first involves the human enzyme NQO1, which is over-expressed in lung, colon and breast tumours. The second technology platform is based upon modification of nucleoside drugs to improve their activity.